Stage 0 Osteonecrosis of the Jaw in a Patient on Denosumab

Overview

Journal J Oral Maxillofac Surg

Specialties Dentistry
General Surgery

Date 2014 Jan 9

PMID 24397946

Citations 17

Authors

Tara L Aghaloo

Sarah M Dry

Sanjay Mallya

Sotirios Tetradis

Affiliations

Soon will be listed here.

Abstract

Osteonecrosis of the jaws (ONJ) is a complex disease involving multiple tissue and cell-type responses to wound healing or infection. AAOMS defines bisphosphonate related ONJ (BRONJ) as exposed, necrotic bone in the maxillofacial region that has persisted for more than 8 weeks in a patient with current or previous antiresorptive treatment, without a history of radiation therapy to the jaws. Since the first reported ONJ cases in 2003 and 2004, there has been little advancement in understanding the etiology and pathophysiology of ONJ. Many hypotheses have been proposed, including bisphosphonate (BP) toxicity to oral epithelium, altered wound healing after tooth extraction, high turnover of the mandible and maxilla, oral biofilm formation, infection and inflammation, and suppression of angiogenesis and bone turnover. The current classification system of ONJ involves stages 0 to 3 and is based on patient clinical presentation. This report describes a case of stage 0 ONJ in a patient on denosumab and indicates the full-spectrum similarities between BP- and denosumab-associated ONJ clinically, radiographically, and histologically.

Citing Articles

Three-dimensional clinical assessment for MRONJ risk in oncologic patients following tooth extractions.

Moreno Rabie C, Fontenele R, Oliveira Santos N, Nogueira Reis F, Van den Wyngaert T, Jacobs R Dentomaxillofac Radiol. 2023; 52(8):20230238.

PMID: 37874081 PMC: 10968756. DOI: 10.1259/dmfr.20230238.

Histopathological significance of necrosis in oral lesions: A review.

Fathima S, Gururaj N, Sivapathasundharam B, Vennila A, Keerthik Lavanya M, Sarayushivani U J Oral Maxillofac Pathol. 2023; 27(2):340-347.

PMID: 37854904 PMC: 10581306. DOI: 10.4103/jomfp.jomfp_39_23.

Osteonecrosis of the Jaw.

Loncar Brzak B, Aleksijevic L, Vindis E, Kordic I, Granic M, Vidovic Juras D Dent J (Basel). 2023; 11(1).

PMID: 36661560 PMC: 9858620. DOI: 10.3390/dj11010023.

Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction.

Moreno-Rabie C, Lapauw L, Gaeta-Araujo H, Ferreira-Leite A, Coucke W, Van den Wyngaert T Sci Rep. 2022; 12(1):11280.

PMID: 35789184 PMC: 9252989. DOI: 10.1038/s41598-022-15254-y.

Inhibition of HMGB1/RAGE Signaling Reduces the Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Mice.

Gkouveris I, Hadaya D, Elzakra N, Soundia A, Bezouglaia O, Dry S J Bone Miner Res. 2022; 37(9):1775-1786.

PMID: 35711109 PMC: 9474692. DOI: 10.1002/jbmr.4637.

References

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-22. PMC: 3090685. DOI: 10.1016/S0140-6736(10)62344-6. View

Diniz-Freitas M, Lopez-Cedrun J, Fernandez-Sanroman J, Garcia-Garcia A, Fernandez-Feijoo J, Diz-Dios P . Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain. Med Oral Patol Oral Cir Bucal. 2012; 17(5):e751-8. PMC: 3482517. DOI: 10.4317/medoral.18041. View

Neuprez A, Coste S, Rompen E, Crielaard J, Reginster J . Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int. 2013; 25(1):393-5. PMC: 3889627. DOI: 10.1007/s00198-013-2437-z. View

Lazarovici T, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N . Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg. 2009; 67(4):850-5. DOI: 10.1016/j.joms.2008.11.015. View

Gotcher J, Jee W . The progress of the periodontal syndrome in the rice cat. II. The effects of a diphosphonate on the periodontium. J Periodontal Res. 1981; 16(4):441-55. DOI: 10.1111/j.1600-0765.1981.tb00995.x. View

Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G . Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol. 2011; 29(17):e521-2. DOI: 10.1200/JCO.2011.35.1551. View

Rogers M, Gordon S, Benford H, Coxon F, Luckman S, Monkkonen J . Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000; 88(12 Suppl):2961-78. DOI: 10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.3.co;2-c. View

Coxon F, Helfrich M, vant Hof R, Sebti S, Ralston S, Hamilton A . Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000; 15(8):1467-76. DOI: 10.1359/jbmr.2000.15.8.1467. View

. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-76. DOI: 10.1016/j.joms.2006.11.003. View

10.

Kang B, Cheong S, Chaichanasakul T, Bezouglaia O, Atti E, Dry S . Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res. 2013; 28(7):1631-40. PMC: 3688704. DOI: 10.1002/jbmr.1894. View

11.

Sonis S, Watkins B, Lyng G, Lerman M, Anderson K . Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2008; 45(2):164-72. DOI: 10.1016/j.oraloncology.2008.04.013. View

12.

Patel S, Choyee S, Uyanne J, Nguyen A, Lee P, Sedghizadeh P . Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis. 2012; 18(7):625-32. DOI: 10.1111/j.1601-0825.2012.01911.x. View

13.

Lacey D, Boyle W, Simonet W, Kostenuik P, Dougall W, Sullivan J . Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012; 11(5):401-19. DOI: 10.1038/nrd3705. View

14.

Ali-Erdem M, Burak-Cankaya A, Cemil-Isler S, Demircan S, Soluk M, Kasapoglu C . Extraction socket healing in rats treated with bisphosphonate: animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients. Med Oral Patol Oral Cir Bucal. 2011; 16(7):e879-83. DOI: 10.4317/medoral.17150. View

15.

Baron R, Ferrari S, Russell R . Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2010; 48(4):677-92. DOI: 10.1016/j.bone.2010.11.020. View

16.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

17.

Dranitsaris G, Hatzimichael E . Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer. 2012; 20(7):1353-60. PMC: 3360851. DOI: 10.1007/s00520-012-1461-4. View

18.

Schwartz H . Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg. 1982; 4(3):251-3. DOI: 10.1002/hed.2890040313. View

19.

Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella R . Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?. J Oral Maxillofac Surg. 2009; 67(3):593-601. DOI: 10.1016/j.joms.2008.09.031. View

20.

Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B . Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2011; 379(9810):39-46. PMC: 3671878. DOI: 10.1016/S0140-6736(11)61226-9. View